Navigation Links
Frost & Sullivan Applauds Definiens' Strong Technology Portfolio for the Effective Data Analysis of Histology Images
Date:12/9/2013

LONDON, Dec. 9, 2013 /PRNewswire/ -- Based on its recent research on the tissue diagnostics and pathology imaging market, Frost & Sullivan presents Definiens with the 2013 Global Frost & Sullivan Award for Company of the Year. In the past, Definiens focused primarily on life sciences but the company is also establishing a toehold in tissue diagnostics and clinical digital pathology. Definiens' proprietary solutions, such as Definiens Tissue Studio® and Definiens Image Miner™, have set industry benchmarks with their unique capabilities to deliver the best-in-class image interpretation and data mining. This enables the morphological features of tissue slides to be rapidly quantitated, a process Definiens refers to as tissue datafication.

Many laboratories still persist with manual methodologies and image scoring platforms to extract and analyze data from histological slides. Definiens' solutions aim to ease the process by offering image analysis and data mining solutions in the area of drug discovery and clinical diagnostic product development. The company's solutions have a flexible architecture that enables rapid prototyping of assays and its technology is uniquely positioned to help improve treatment outcomes for patients and aids the development of personalized medicine.

The reason for Definiens' leading position in the area of tissue datafication lies in its patented Definiens Cognition Network Technology®, which mimics the human mind's cognitive powers to reposition knowledge within a semantic network. This technology, invented by Nobel Prize winner Gerd Binnig, is able to understand and analyze image features in the context of their surroundings--something no other solution can achieve.  Therefore, due to its ability to accelerate cellular biomarker screening and translational research, Definiens' technology will be a game changer in the drug discovery proc
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
4. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... July 31, 2014 Nektar Therapeutics (Nasdaq: ... quarter ended June 30, 2014. Cash and ... million as compared to $309.1 million at March 31, 2014."The ... Nektar as we look forward to significant milestones for a ... President and Chief Executive Officer of Nektar. "The first of ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4
(Date:8/1/2014)... Cannabis use among young people has spiked, ... 17 having used marijuana at least once and 17 percent ... ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from the ... this summer with factual information about drugs, to help reverse ... “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers have ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... Gray HealthDay Reporter FRIDAY, Aug. ... in manufacturing jobs may have significantly less endurance than those who ... 32 people -- half were obese, half were of normal weight ... about 60 percent longer. Obesity also was associated with less ... Being older -- 50 to 65 years of age -- neither ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2
... WEDNESDAY, Oct. 26 (HealthDay News) -- A vaccine to prevent ... bisexual males, according to a study funded in part by ... papilloma virus (HPV), the most common sexually transmitted disease in ... and bisexual men and people infected with HIV. , ...
... the nipple is highly effective in animal models of early ... patients, according to a report by Johns Hopkins Kimmel Cancer ... 26. The results of the study are expected to lead ... early breast cancer. "Our results support the theory that ...
... human eye is as comfortable with white light generated ... popular light-emitting diodes (LEDs), according to tests conceived at ... through material to generate light, but the simpler LED ... light back and forth internally before releasing it. ...
... University Hospital surgeons found that a carefully-selected surgical care ... by nearly 50 percent. Smoking cessation at ... prior to skin closure, and using clippers over razors to ... helped reduced infection rates, according to the study published in ...
... what is so far the largest investigation of its kind, ... diseases and how they are affected by differences between two ... highly targeted, individualized therapies. Led by researchers from Weill ... edition of the journal Nature , the study provides ...
... Bisphenol A (BPA) -- a substance that may have ... thermal cash register receipts, scientists are reporting. The recycling ... BPA contamination of paper napkins, toilet paper, food packaging ... special implications for cashiers and other people who routinely ...
Cached Medicine News:Health News:HPV Vaccine Might Help Prevent Anal Cancers: Study 2Health News:Through-the-nipple breast cancer therapy shows promise in early tests 2Health News:Through-the-nipple breast cancer therapy shows promise in early tests 3Health News:High-quality white light produced by four-color laser source 2Health News:High-quality white light produced by four-color laser source 3Health News:Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures 2Health News:Study identifies genetic basis of human metabolic individuality 2
Precision has its new line of programmable autoclaves which are easy to use bench-top autoclaves or models to fit any need. It has 4 adjustable sterilization programs, touch button control panel, man...
HRT II is the smallest scanning laser ever, light, portable and ready for telemedicine....
... The Horizon Phacoemulsification System ... surgical system. Lightweight and portable, ... features in a small console. ... necessary to perform anterior segment ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: